Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Change in Accured Expenses (2020 - 2025)

HCW Biologics (HCWB) has disclosed Change in Accured Expenses for 6 consecutive years, with -$362123.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 174.42% year-over-year to -$362123.0, compared with a TTM value of -$3.6 million through Sep 2025, down 126.77%, and an annual FY2024 reading of $11.9 million, up 633.3% over the prior year.
  • Change in Accured Expenses was -$362123.0 for Q3 2025 at HCW Biologics, up from -$373905.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $9.4 million in Q2 2024 and bottomed at -$2.4 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $666614.4, with a median of $489763.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 250.21% in 2022, then skyrocketed 1801.51% in 2024.
  • Year by year, Change in Accured Expenses stood at -$72913.0 in 2021, then skyrocketed by 951.96% to $621187.0 in 2022, then surged by 97.45% to $1.2 million in 2023, then crashed by 141.45% to -$508404.0 in 2024, then increased by 28.77% to -$362123.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for HCWB at -$362123.0 in Q3 2025, -$373905.0 in Q2 2025, and -$2.4 million in Q1 2025.